Sherman L G, Liang C, Boden W E, Hood W B
Circ Res. 1981 Feb;48(2):224-32. doi: 10.1161/01.res.48.2.224.
The effect of verapamil, an inhibitor of transmembrane calcium flux, was studied in intact conscious dogs with myocardial ischemia produced by inflating a balloon cuff implanted on the left anterior descending coronary artery. Six dogs received a continuous infusion of verapamil (10 microgram/kg per min) beginning prior to coronary occlusion, and six received normal saline infusions. Systolic ejection shortening (SES) was measured from subendocardial ultrasonic crystals implanted in the central ischemic zone (IZ) and border zone (BZ), and in a nonischemic control zone (CZ). Hearts were paced at a constant heart rate with periodic introduction of closely coupled extrasystoles. SES was measured both for normally paced beats and during postextrasystolic potentiation (PESP). Regional myocardial blood flow was measured by injecting radioactive microspheres before, during, and after coronary occlusion. There were no significant differences between verapamil-treated dogs and saline control dogs in mean aortic pressure, heart rate, left ventricular end-diastolic pressure or dP/dt, cardiac output, or regional myocardial blood flow in IZ, BZ, or CZ. Differences in mechanical performance between two groups were noted, however. In the IZ, SES was abolished completely for normally paced beats in both groups but was significantly preserved for PESP beats in the verapamil-treated animals. In the BZ, SES was significantly reduced for normally paced beats only in the saline controls, and PESP responses were preserved to a significantly greater degree in the verapamil-treated animals. These results indicate that verapamil pretreatment exerts beneficial effects upon mechanical performance of ischemic myocardium. Since no changes in systemic hemodynamics or regional myocardial blood flow were observed, the effect may be due to the calcium-antagonistic properties of the agent.
在完整清醒的犬身上,通过向植入左冠状动脉前降支的球囊袖带充气制造心肌缺血,研究了跨膜钙通量抑制剂维拉帕米的作用。6只犬在冠状动脉闭塞前开始持续输注维拉帕米(10微克/千克每分钟),另外6只接受生理盐水输注。通过植入中央缺血区(IZ)、边缘区(BZ)和非缺血对照区(CZ)的心内膜下超声晶体测量收缩期射血缩短(SES)。以恒定心率起搏心脏,并定期引入紧密耦合的期前收缩。分别测量正常起搏搏动和期前收缩后增强(PESP)期间的SES。在冠状动脉闭塞前、期间和之后,通过注射放射性微球测量局部心肌血流量。维拉帕米治疗组犬和生理盐水对照组犬在平均主动脉压、心率、左心室舒张末期压力或dP/dt、心输出量,或IZ、BZ或CZ的局部心肌血流量方面均无显著差异。然而,两组在机械性能方面存在差异。在IZ,两组正常起搏搏动的SES均完全消失,但维拉帕米治疗组动物的PESP搏动的SES显著保留。在BZ,仅生理盐水对照组正常起搏搏动的SES显著降低,维拉帕米治疗组动物的PESP反应保留程度显著更高。这些结果表明,维拉帕米预处理对缺血心肌的机械性能具有有益作用。由于未观察到全身血流动力学或局部心肌血流量的变化,该作用可能归因于该药物的钙拮抗特性。